|
|
Volumn 344, Issue , 2012, Pages
|
|
How the FDA forgot the evidence: the case of donepezil 23 mg.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
DONEPEZIL;
INDAN DERIVATIVE;
NOOTROPIC AGENT;
PIPERIDINE DERIVATIVE;
ALZHEIMER DISEASE;
ARTICLE;
DRUG APPROVAL;
DRUG LABELING;
EVIDENCE BASED MEDICINE;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
MARKETING;
METHODOLOGY;
STANDARD;
UNITED STATES;
ALZHEIMER DISEASE;
DRUG APPROVAL;
DRUG LABELING;
EVIDENCE-BASED MEDICINE;
HUMANS;
INDANS;
MARKETING;
NOOTROPIC AGENTS;
PIPERIDINES;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 84860589951
PISSN: None
EISSN: 17561833
Source Type: Journal
DOI: 10.1136/bmj.e1086 Document Type: Article |
|
Times cited : (25)
|
|
References (0)
|
